Notice of Completion of Acquisition of Treasury Shares
(Acquisition of Treasury Shares pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, January 21, 2008 – Astellas Pharma Inc. (“the Company”, headquarters: Tokyo, President and CEO: Masafumi Nogimori) announced that it completed acquisition of its Treasury Shares, which was resolved by its Board of Directors on November 22, 2007, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act:

Particulars

1. Class of shares acquired: Common stock of the Company
2. Total number of shares acquired: 8 million shares
3. Total value of acquisition: ¥ 38,684,248,000

(Reference)

Resolution of the Board of Directors on November 22, 2007

(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: 8 million shares (Maximum)
(3) Aggregate amount of acquisition cost: 40 billion yen (Maximum)
(4) Period of acquisition: From December 3, 2007 to January 18, 2008

Contacts for inquiries or additional information
Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 Fax: +81-3-5201-7473
http://www.astellas.com